FDA's Arthritis Advisory Committee
This article was originally published in The Tan Sheet
Executive Summary
On Jan. 28, the committee will address its "role...in the review" of Rx-to-OTC switches as well as "NDA Day" procedures and objectives. In June, the arthritis committee participated in a review of Syntex/P&G's Rx-to-OTC switch application for naproxen sodium with FDA's Nonprescription Drugs Advisory Committee. The first day of the meeting on Jan. 27 will be devoted to a review of Greenwich Pharmaceutical's NDA for Therafectin, a prescription drug. The meeting is scheduled to begin at 8:30 a.m. each day in conference rooms D & E of FDA's Parklawn Building in Rockville, Md
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: